FORM8-K HILLENBRAND,INC.

Similar documents
FORM8-K HILLENBRAND,INC.

HILLENBRAND INDUSTRIES INC

WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006

DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

WALGREENS BOOTS ALLIANCE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

RULES OF CONDUCT OF INSIDERS RESPECTING

Capital Senior Living Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

January 30, 2018 Dow Wilson President and Chief Executive Officer

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

For personal use only

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

For personal use only

Tamsulosin Hydrochloride 0.4 mg Capsule

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Genomic Health. Kim Popovits, Chairman, CEO and President

Investor Presentation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

The Dental Corporation Opportunity

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

Investment in MGC Pharmaceuticals

WASHINGTON,D.C FORM8-K. CurrentReport PursuanttoSection13or15(d)ofthe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter)

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

Forward-Looking Statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

New Markets Tax Credit CDE Certification Question & Answer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017.

No Stomach For Cancer

Q3 18 Earnings Supplemental Slides

BVI Limited Partnership Hedge Funds: Calling Japan

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

Investor Presentation June 2012 NASDAQ: CEMI

CSA Briefing Note Regarding Joint Application against the University and Re-Commencing Collection of CFS/CFS-O Fees

The acquisition of Fortitech

QUESTIONNAIRE ANTI MONEY LAUNDERING (Including Counter Terrorist Financing, Financial Sanctions Monitoring, KYC)

Operational Efficiency:

Employment Contract. This sample employment contract is from Self-Employment vs. Employment Status, CDHA (no date available)

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

Do not edit or delete any questions from this application. Doing so will result in immediate disqualification of your request.

Exhibit 2 RFQ Engagement Letter

Dealdoc Collaborative R&D and marketing agreement for diabetes product portfolio

DARA Reports Year-End 2012 Financial Results

Investing in Dental Practice Management: Key Issues and Notable Transactions

Mental Toronto Hydro

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

Oragenics Shareholder Update

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

DW PENNICHUCK EAST UTILITY, INC. Petition for Franchise Approval and Rates. Order Nisi Approving Franchise and Rate Petition

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

www. isotopeworld.com Advanced Medical Isotope Corporation

Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

Summary of Results for the First Half of FY2015/3

Designing a Smoke-Free Future

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

MIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE

A world leader in allergy immunotherapy

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

Endesa 1Q 2017 Results 09/05/2017

34 th Annual J.P. Morgan Healthcare Conference

Company overview. Highlights for the 1 st quarter 2018 (January-March)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam

Constitution for the National Association to Advance Fat Acceptance, Inc. PREAMBLE

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Forward Looking Information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

Report to the GAVI Alliance Board 7-8 July 2011

Teaming Agreement. Grant of Charter and License. Dues. Name and Logo. Mission Commitment. Chapter Standards Compliance.

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

FIRSTQUARTER2018 RESULTSPRESENTATION

Itamar Medical. December Investors Presentation.

Transcription:

UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015 HILLENBRAND,INC. (Exact Name of Registrant as Specified in Charter) Indiana 1-33794 26-1342272 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.) Incorporation) OneBatesvilleBoulevard Batesville,Indiana 47006 (Address of Principal Executive Office) (Zip Code) Registrant s telephone number, including area code: (812)934-7500 NotApplicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o o o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item8.01.OtherEvents. On December 18, 2015, a wholly-owned subsidiary of Hillenbrand, Inc. ( Hillenbrand ) entered into an agreement to acquire Red Valve Company, Inc. ( Red Valve ) from its shareholders, as well as an agreement to acquire certain real estate used by Red Valve from Corinthian Realty, L.L.C. ( Corinthian ) (the Transaction ). The aggregate purchase price for the Transaction is $131,864,000 in cash, subject to certain post-closing adjustments, with $3,300,000 of the purchase price being paid to Corinthian for the real estate. The Transaction is expected to close within approximately thirty days, subject to regulatory approval and customary closing conditions. Based in Carnegie, Pennsylvania, Red Valve is a global leader in highly-engineered valves designed for municipal and industrial wastewater applications. Attached as Exhibit 99.1 hereto is a copy of the press release issued by Hillenbrand regarding the Transaction. The information furnished pursuant to Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ( Exchange Act ), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any Hillenbrand filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item9.01.FinancialStatementsandExhibits. (d) Exhibits. ExhibitNumber Description 99.1 Press Release, dated December 22, 2015, of Hillenbrand, Inc. DisclosureRegardingForward-LookingStatements Throughout the press release we make a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As the words imply, these are forward-looking statements about future plans, objectives, beliefs, and expectations that might or might not happen in the future. As contrasted with historical information, forward-looking statements are based on assumptions that we believe are reasonable, but by their very nature are subject to a wide range of risks. Words that could indicate we are making forward-looking statements include the following: intend believe plan expect may goal would become pursue estimate will forecast continue could targeted encourage promise improve progress potential should This is not an exhaustive list, but is intended to give you an idea of how we try to identify forward-looking statements. The absence of any of these words, however, does not mean that the statement is not forward-looking. Here is the key point: forward-looking statements are not guarantees of future performance, and our actual results could differ materially from those set forth in any forward-looking statements. Any number of factors, many of which are beyond our control, could cause our performance to differ significantly from what is described in the forward-looking statements. These factors include, but are not limited to: the occurrence of any event, change or other circumstance that could prevent or delay the closing of the Transaction; the outcome of any legal proceedings that may be instituted against Hillenbrand, its affiliates, Red Valve, Corinthian or others following announcement of the Transaction; the inability to satisfy the conditions to complete the Transaction (or to complete the Transaction on a timely basis), including the receipt of required regulatory approvals; risks that the proposed Transaction disrupts current operations or poses potential difficulties in employee retention or otherwise affects financial or operating results; the ability to recognize the benefits of the Transaction, including 2

potential accretion to Hillenbrand s earnings, potential synergies and cost savings or the failure of Red Valve to achieve its plans and objectives generally; and legislative, regulatory and economic developments. For a discussion of factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading Risk Factors in Item 1A of Part I of our Form 10-K for the period ended September 30, 2015, located on our website and filed with the Securities and Exchange Commission. We assume no obligation to update or revise any forward-looking information. 3

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DATE: December 22, 2015 HILLENBRAND,INC. BY: /S/ Nicholas R. Farrell Nicholas R. Farrell Vice President, General Counsel and Secretary 4

EXHIBITINDEX ExhibitNumber Description 99.1 Press Release, dated December 22, 2015, of Hillenbrand, Inc. 5

Exhibit99.1 HillenbrandtoAcquireRedValve Acquisition advances Hillenbrand s world-class global diversified industrial growth strategy, complementing the recent ABEL acquisition in the flow control space. BATESVILLE,Ind.Dec.22,2015 /PR Newswire / Hillenbrand, Inc. (NYSE: HI) has entered into a definitive agreement to acquire Red Valve Company, Inc. for $131.9 million in cash, including $3.3 million for related real estate. The transaction is expected to close within 30 days, upon receipt of regulatory approval. Based in Carnegie, Pa., Red Valve is a global leader in highly-engineered valves designed to operate in the harshest municipal and industrial wastewater environments. Its products support mission critical applications in water, power and mining and other general industrial markets. At the completion of the transaction, Red Valve will join Hillenbrand s Process Equipment Group, which includes ABEL, a globally-recognized leader in positive displacement pumps. This acquisition advances Hillenbrand s strategy to transform into a world-class global diversified industrial company, said Joe Raver, President and CEO of Hillenbrand. We believe Red Valve will complement our recent ABEL acquisition, increasing our ability to expand into new end markets and geographies within the highly attractive flow control space. During the trailing 12-month period ending on Nov. 30, 2015, Red Valve s revenue was approximately $38.6 million, and its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was nearly $12.1 million, excluding $1.9 million in non-recurring expenses. We are excited about the opportunities Hillenbrand brings to our company, said Chris Raftis, President of Red Valve. Hillenbrand has a global footprint that provides us with a significant opportunity for international growth and we look forward to working with the company to achieve our strategic vision. Hillenbrand expects to use cash on hand and cash available under its revolving credit facility to fund this acquisition. The transaction is expected to be accretive to Hillenbrand s 2016 adjusted earnings per share, net of acquisition costs. EC Mergers & Acquisitions, a EuroConsult company, acted as exclusive financial adviser to the shareholders of Red Valve. AboutHillenbrand Hillenbrand (www.hillenbrand.com) is a global diversified industrial company with multiple market-leading brands that serve a wide variety of industries across the globe. We pursue profitable growth and robust cash generation in order to drive increased value for our shareholders. Hillenbrand s portfolio is composed of two business segments: the Process Equipment Group and Batesville. The Process Equipment Group businesses design, develop, manufacture and service highly engineered industrial equipment around the world. Batesville is a recognized leader in the North American death care industry. Hillenbrand is publicly traded on the NYSE under HI. AboutRedValve Red Valve Company (www.redvalve.com) is the world s largest manufacturer of pinch valves and Tideflex Check Valves and has an international reputation for quality-engineered valves designed for long life in the toughest municipal and industrial applications. Red

Valve s advanced elastomer technology is engineered into every Red Valve pinch valve, control valve, slurry knife gate valve, pressure sensor, Redflex Expansion Joint and revolutionary all-rubber Tideflex Check Valve. CONTACTS CorporateCommunicationsforHillenbrand Tory Flynn, Director, Corporate Communications Phone: 812-931-5024 E-mail: Tory.Flynn@Hillenbrand.com InvestorRelationsforHillenbrand Chris Gordon, Director, Investor Relations Phone: 812-931-5001 E-mail: Chris.Gordon@Hillenbrand.com